Abstract
Introduction: Clear communication of diagnostic test results and dementia diagnosis is challenging yet important to empower patients and care partners. A personalized diagnostic report could support the communication of dementia diagnostics and aid patients' understanding of diagnosis. In this study, we aimed to design a diagnostic report in co-creation with patients and care partners.
Methods: We used a mixed-methods approach, combining surveys with focus groups in iteration. Phase 1 consisted of an international survey assessing needs among patients ( n = 50) and care partners ( n = 46), and phase 2 consisted of focus group meetings ( n = 3) to co-create the content and to hands-on co-design the layout of the diagnostic report with patients ( n = 7) and care partners ( n = 7). Phase 3 validated results from phase 2 in a survey among patients ( n = 28) and care partners ( n = 12), and phase 4 comprised final feedback by dementia (care) experts ( n = 5). Descriptive statistics were used to report quantitative results and directed content analysis was used to analyze qualitative data.
Results: Most patients (39/50, 78%) and care partners (38/46, 83%) positively valued a diagnostic report to summarize test results. The report should be brief, straightforward, and comprise results of the diagnostic tests, including brain imaging and information on future expectations. Despite a clear preference for visual display of test results, several visualization options were deemed best and were equally comprehended.
Discussion: In this study, we developed a prototype of a personalized patient report through an iterative design process and learned that co-creation is highly valuable to meet the specific needs of end-users.
Original language | English |
---|---|
Article number | e12333 |
Pages (from-to) | e12333 |
Journal | Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring |
Volume | 14 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2022 |
Keywords
- brain imaging
- communication
- dementia
- diagnosis
- diagnostic testing
- neuropsychology
- prevention
- prognosis
- progression
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol. 14, No. 1, e12333, 2022, p. e12333.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Development and design of a diagnostic report to support communication in dementia
T2 - Co-creation with patients and care partners
AU - van Gils, Aniek M
AU - Visser, Leonie N C
AU - Hendriksen, Heleen M A
AU - Georges, Jean
AU - van der Flier, Wiesje M
AU - Rhodius-Meester, Hanneke F M
N1 - Funding Information: HRM performs contract research for Combinostics; all funding is paid to her institution. WF performs contract research for Biogen. Research programs of WF have been funded by ZonMW, NWO, EU‐FP7, EU‐JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health‐Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes‐Strijbis fonds, stichting Equilibrio, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc., Novartis‐NL, Life‐MI, AVID, Roche BV, Fujifilm, Combinostics. WF holds the Pasman chair. WF is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health‐Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106). WF has performed contract research for Biogen MA Inc. and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc., Danone, Eisai, WebMD Neurology (Medscape), Springer Healthcare. WF is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF participated in advisory boards of Biogen MA Inc. and Roche; all funding is paid to her institution. WF was associate editor of in 2020/2021. WF is associate editor at . JG is Executive Director of Alzheimer Europe which receives funding from EU research and health programmes as well as private foundations and companies. All other coauthors report no conflicts of interest. Alzheimer, Research & Therapy Brain Funding Information: Research of the Alzheimer's Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Vrije Universiteit Medical Center Alzheimer Center is supported by the Stichting Alzheimer Nederland and Stichting Vrije Universiteit Medical Center Fonds. The collaboration project Dementia diagnostics using Artificial Intelligence (DAILY; project number LSHM19123-HSGF) is co-funded by the public–private partnership allowance made available by Health-Holland, Top Sector Life Sciences, and Health to stimulate public-private partnerships and Combinostics. The chair of WF is supported by the Pasman Stichting. WF and LV are recipients of ABOARD, which is a public-private partnership receiving funding from ZonMW (number 73305095007) and Health-Holland, Top Sector Life Sciences and Health (public-private partnership allowance; number LSHM20106). LV is supported by a fellowship grant received from Alzheimer Nederland (WE.15-2019-05). HRM is recipient of the Memorabel Dementia Fellowship 2021 (ZonMw project number 10510022110004). WF, LV, and JG are recipients of the EU Joint Programme-Neurodegenerative Disease Research (JPND) project EURO-FINGERS (ZonMW-Memorabel #733051102), which is supported through the following funding organizations under the aegis of Joint Programme-Neurodegenerative Disease: Finland, Academy of Finland; Germany, Federal Ministry of Education and Research; Spain, National Institute of Health Carlos III; Luxemburg, National Research Fund; Hungary, National Research, Development, and Innovation Office; The Netherlands, Netherlands Organisation for Health Research and Development; and Sweden, Swedish Research Council (grant agreement INTER/JPND/19/BM/14012609). These funding sources were not involved in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. Funding Information: Research of the Alzheimer's Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Vrije Universiteit Medical Center Alzheimer Center is supported by the Stichting Alzheimer Nederland and Stichting Vrije Universiteit Medical Center Fonds. The collaboration project Dementia diagnostics using Artificial Intelligence (DAILY; project number LSHM19123‐HSGF) is co‐funded by the public–private partnership allowance made available by Health‐Holland, Top Sector Life Sciences, and Health to stimulate public‐private partnerships and Combinostics. The chair of WF is supported by the Pasman Stichting. WF and LV are recipients of ABOARD, which is a public‐private partnership receiving funding from ZonMW (number 73305095007) and Health‐Holland, Top Sector Life Sciences and Health (public‐private partnership allowance; number LSHM20106). LV is supported by a fellowship grant received from Alzheimer Nederland (WE.15‐2019‐05). HRM is recipient of the Memorabel Dementia Fellowship 2021 (ZonMw project number 10510022110004). WF, LV, and JG are recipients of the EU Joint Programme‐Neurodegenerative Disease Research (JPND) project EURO‐FINGERS (ZonMW‐Memorabel #733051102), which is supported through the following funding organizations under the aegis of Joint Programme‐Neurodegenerative Disease: Finland, Academy of Finland; Germany, Federal Ministry of Education and Research; Spain, National Institute of Health Carlos III; Luxemburg, National Research Fund; Hungary, National Research, Development, and Innovation Office; The Netherlands, Netherlands Organisation for Health Research and Development; and Sweden, Swedish Research Council (grant agreement INTER/JPND/19/BM/14012609). These funding sources were not involved in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. Publisher Copyright: © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
PY - 2022
Y1 - 2022
N2 - Introduction: Clear communication of diagnostic test results and dementia diagnosis is challenging yet important to empower patients and care partners. A personalized diagnostic report could support the communication of dementia diagnostics and aid patients' understanding of diagnosis. In this study, we aimed to design a diagnostic report in co-creation with patients and care partners.Methods: We used a mixed-methods approach, combining surveys with focus groups in iteration. Phase 1 consisted of an international survey assessing needs among patients ( n = 50) and care partners ( n = 46), and phase 2 consisted of focus group meetings ( n = 3) to co-create the content and to hands-on co-design the layout of the diagnostic report with patients ( n = 7) and care partners ( n = 7). Phase 3 validated results from phase 2 in a survey among patients ( n = 28) and care partners ( n = 12), and phase 4 comprised final feedback by dementia (care) experts ( n = 5). Descriptive statistics were used to report quantitative results and directed content analysis was used to analyze qualitative data. Results: Most patients (39/50, 78%) and care partners (38/46, 83%) positively valued a diagnostic report to summarize test results. The report should be brief, straightforward, and comprise results of the diagnostic tests, including brain imaging and information on future expectations. Despite a clear preference for visual display of test results, several visualization options were deemed best and were equally comprehended.Discussion: In this study, we developed a prototype of a personalized patient report through an iterative design process and learned that co-creation is highly valuable to meet the specific needs of end-users.
AB - Introduction: Clear communication of diagnostic test results and dementia diagnosis is challenging yet important to empower patients and care partners. A personalized diagnostic report could support the communication of dementia diagnostics and aid patients' understanding of diagnosis. In this study, we aimed to design a diagnostic report in co-creation with patients and care partners.Methods: We used a mixed-methods approach, combining surveys with focus groups in iteration. Phase 1 consisted of an international survey assessing needs among patients ( n = 50) and care partners ( n = 46), and phase 2 consisted of focus group meetings ( n = 3) to co-create the content and to hands-on co-design the layout of the diagnostic report with patients ( n = 7) and care partners ( n = 7). Phase 3 validated results from phase 2 in a survey among patients ( n = 28) and care partners ( n = 12), and phase 4 comprised final feedback by dementia (care) experts ( n = 5). Descriptive statistics were used to report quantitative results and directed content analysis was used to analyze qualitative data. Results: Most patients (39/50, 78%) and care partners (38/46, 83%) positively valued a diagnostic report to summarize test results. The report should be brief, straightforward, and comprise results of the diagnostic tests, including brain imaging and information on future expectations. Despite a clear preference for visual display of test results, several visualization options were deemed best and were equally comprehended.Discussion: In this study, we developed a prototype of a personalized patient report through an iterative design process and learned that co-creation is highly valuable to meet the specific needs of end-users.
KW - brain imaging
KW - communication
KW - dementia
KW - diagnosis
KW - diagnostic testing
KW - neuropsychology
KW - prevention
KW - prognosis
KW - progression
UR - http://www.scopus.com/inward/record.url?scp=85145054894&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/dad2.12333
DO - https://doi.org/10.1002/dad2.12333
M3 - Article
C2 - 36092691
SN - 2352-8729
VL - 14
SP - e12333
JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
IS - 1
M1 - e12333
ER -